NextCell Pharma AB (SE:NXTCL)

:NXTCL

NXTCL

NextCell Pharma AB

RESEARCH TOOLSreports

Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr130.55M

Enterprise Valuekr99.62M

Total Cash (Recent Filing)kr26.03M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.41

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding111,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetMaintaining zero reported debt materially reduces refinancing and interest-rate exposure, giving management flexibility to fund R&D and operations via equity or partnerships. Over a 2–6 month horizon this structural feature lowers solvency risk compared with leveraged peers and supports strategic options.

Focused MSC-based PipelineA clear strategic focus on MSC-derived therapies creates specialized know‑how and potential competitive moats in regenerative medicine. Structural demand for autoimmune and inflammatory treatments supports long development cycles and sustained R&D investment relevance over months to years.

Lean Operating BaseA small, concentrated team implies lower fixed overhead and the ability to allocate limited resources directly to core R&D. Over the medium term this lean structure can extend runway per funding round and enable nimble clinical program execution relative to larger, costlier organizations.

Bears Say

High Cash BurnSustained negative operating and free cash flow indicate the company consumes material cash to fund operations and trials. Without improved operating results or external financing, this structural cash burn will require capital raises, diluting shareholders or constraining program timing over the coming months.

Persistent Operating LossesNegative gross profit and deeply negative margins show the cost base exceeds revenues, signaling no near-term path to break‑even. This undermines self-sustaining growth prospects and means the business will remain dependent on external funding until revenue model or cost structure changes materially.

Shrinking Equity BaseA materially reduced equity base weakens the balance sheet buffer against future losses and increases the likelihood of additional capital raises. Over months this elevates funding and dilution risk, and limits flexibility to absorb operational setbacks or accelerate clinical programs without new financing.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr130.55M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 6 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -kr0.079 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.021.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.079 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 0.787%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB (NXTCL) is a Swedish biopharmaceutical company focused on the development and commercialization of advanced therapies for immune-related diseases. The company specializes in stem cell-based treatments, with its flagship product, ProTrans, developed for the treatment of autoimmune conditions such as Type 1 Diabetes. NextCell Pharma operates within the biotechnology and healthcare sectors, aiming to leverage cutting-edge research to provide innovative therapeutic solutions.